P. Vicini

发表

An Approach to Determining Intracranial Pressure Variability Capable of Predicting Decreased Intracranial Adaptive Capacity in Patients With Traumatic Brain Injury

Jun-Yu Fan, C. Kirkness, P. Vicini, 2010, Biological research for nursing.

Precision medicine in the age of big data: The present and future role of large‐scale unbiased sequencing in drug discovery and development

J. Vockley, P. Vicini, O. Fields, 2016, Clinical pharmacology and therapeutics.

A review of quantitative modeling of B cell responses to antigenic challenge

P. Vicini, S. Nayak, T. Hickling, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Cellular signaling identifiability analysis: a case study.

P. Vicini, Ryan T. Roper, M. Pia Saccomani, 2010, Journal of theoretical biology.

A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics

P. Vicini, T. Hickling, Xiaoying Chen, 2013, The AAPS Journal.

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition

A. Popel, P. Vicini, B. Wang, 2017, Journal of The Royal Society Interface.

Model-based approaches to biomarker discovery and evaluation: a multidisciplinary integrated review.

P. Vicini, M. Gastonguay, D. Foster, 2002, Critical reviews in biomedical engineering.

Intracranial pressure waveform morphology and intracranial adaptive capacity.

Jun-Yu Fan, C. Kirkness, P. Vicini, 2008, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

Kinetic modeling in support of radionuclide dose assessment.

A. Rescigno, A. Brill, P. Vicini, 2008, Seminars in nuclear medicine.

Evaluation of compartmental and spectral analysis models of [/sup 18/F]FDG kinetics for heart and brain studies with PET

C. Cobelli, A. Lammertsma, A. Lammertsma, 1998, IEEE Transactions on Biomedical Engineering.

Simulating pharmacokinetic and pharmacodynamic fuzzy-parameterized models: a comparison of numerical methods

Paolo Vicini, Kok-Yong Seng, Ivan Nestorov, 2007, Journal of Pharmacokinetics and Pharmacodynamics.

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1—Theoretical Model

P Vicini, P. Vicini, T. Hickling, 2014, CPT: pharmacometrics & systems pharmacology.

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model Applications

P Vicini, P. Vicini, T. Hickling, 2014, CPT: pharmacometrics & systems pharmacology.

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

P. Vicini, T. Hickling, Xiaoying Chen, 2015, Journal of immunology research.

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.

J. Emerson, R. Gibson, M. Rosenfeld, 2001, The Journal of pediatrics.

Blood-Tissue Exchange Modelling

J. Bassingthwaighte, P. Vicini, 2014 .

Chapter 13 – Blood-Tissue Exchange Modelling

P. Vicini, 2001 .

Cellular energetics analysis by a mathematical model of energy balance: estimation of parameters in human skeletal muscle.

P Vicini, M J Kushmerick, M. Kushmerick, 2000, American journal of physiology. Cell physiology.

The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.

P. Vicini, J. Burnett, P. Barrett, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan?

P Vicini, P. Vicini, P. Graaf, 2013, Clinical pharmacology and therapeutics.

Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors

S. Yamazaki, P. Vicini, Ying Jiang, 2013, Drug Metabolism and Disposition.

Quantitative Magnetic Resonance Imaging Analysis of Neovasculature Volume in Carotid Atherosclerotic Plaque

Chun Yuan, Paolo Vicini, Thomas Hatsukami, 2003, Circulation.

Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart and Human Insulin

P. Vicini, H. Poulsen, S. Ingwersen, 2003, Journal of Pharmacokinetics and Pharmacodynamics.

Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women

Paolo Vicini, Mark C. Peterson, Marc R. Gastonguay, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach.

Alessandra Bertoldo, Claudio Cobelli, Paolo Vicini, 2010, American journal of physiology. Endocrinology and metabolism.

Glucose Minimal Model population analysis: Likelihood function profiling via Monte Carlo sampling

C. Cobelli, A. Bertoldo, P. Vicini, 2008, 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules.

Paolo Vicini, P. Vicini, S. Kahn, 2006, American journal of physiology. Endocrinology and metabolism.

Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches

C. Cobelli, A. Bertoldo, P. Vicini, 2006, 2006 International Conference of the IEEE Engineering in Medicine and Biology Society.

The glucose minimal model: Population vs individual parameter estimation

C. Cobelli, A. Bertoldo, P. Vicini, 2006 .

The iterative two-stage population approach to IVGTT minimal modeling: improved precision with reduced sampling. Intravenous glucose tolerance test.

P Vicini, C Cobelli, C. Cobelli, 2001, American journal of physiology. Endocrinology and metabolism.

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration

B. Sandmaier, D. Salinger, P. Vicini, 2014, Cancer Chemotherapy and Pharmacology.

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab

B. Wang, P. Vicini, L. Roskos, 2017, CPT: pharmacometrics & systems pharmacology.

Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study

P. Vicini, B. Winikoff, T. Easterling, 2013, BJOG : an international journal of obstetrics and gynaecology.

Population modeling of tumor growth inhibition in vivo : application to anticancer drug development

P. Vicini, M. Rogge, M. Dodds, 2004 .

approach labeled IVGTT two-compartment minimal model Epinephrine effects on insulin-glucose dynamics: the

C. Cobelli, A. Avogaro, P. Vicini, 2016 .

Pubertal changes in HOMA and QUICKI: relationship to hepatic and peripheral insulin sensitivity

C. Cobelli, P. Vicini, R. Hoffman, 2004, Pediatric diabetes.

Epinephrine effects on insulin-glucose dynamics: the labeled IVGTT two-compartment minimal model approach.

C. Cobelli, A. Avogaro, P. Vicini, 2002, American Journal of Physiology. Endocrinology and Metabolism.

Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future

Y. Daali, L. Lesko, L. Aarons, 2017, Clinical pharmacology and therapeutics.

Ketorolac tromethamine: stereo‐specific pharmacokinetics and single‐dose use in postoperative infants aged 2–6 months

P. Vicini, G. Anderson, A. Lynn, 2011, Paediatric anaesthesia.

Postoperative Ketorolac Tromethamine Use in Infants Aged 6–18 Months: The Effect on Morphine Usage, Safety Assessment, and Stereo-Specific Pharmacokinetics

D. Salinger, P. Vicini, R. Ellenbogen, 2007, Anesthesia and analgesia.

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

S. Yamazaki, P. Vicini, J. Lucas, 2016, Clinical Cancer Research.

Protective Effects of Benzisothiazolylamidines on IL-1β Induced Alterations in Human Articular Chondrocyte Metabolism

V. Cardile, P. Vicini, A. Panico, 2004, Inflammation.

Comparison of Statistical Data Models for Identifying Differentially Expressed Genes Using a Generalized Likelihood Ratio Test

R. Glenny, S. Gharib, P. Vicini, 2008, Gene regulation and systems biology.

Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical Practice

C. Cobelli, P. Vicini, S. Caritis, 2009, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group

D. Salinger, P. Vicini, D. Blough, 2009, Journal of clinical pharmacology.

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model

Paolo Vicini, Shinji Yamazaki, Pei-Pei Kung, 2011, Journal of Pharmacology and Experimental Therapeutics.

Translational Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros

S. Yamazaki, H. Zou, P. Vicini, 2014 .

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer

B. Wang, A. Popel, E. Gabrielson, 2019, The AAPS Journal.

Organ Dose Estimates for Hyperthyroid Patients Treated with 131I: An Update of the Thyrotoxicosis Follow-Up Study

A. Brill, P. Vicini, D. Kwon, 2015, Radiation research.

The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis.

P. Vicini, D. Becker, V. Arena, 2009, The Journal of clinical endocrinology and metabolism.

Undermodeling affects minimal model indexes: insights from a two-compartment model.

Claudio Cobelli, Paolo Vicini, Andrea Caumo, 1999, American journal of physiology. Endocrinology and metabolism.

Estimation of Blood Flow Heterogeneity in Human Skeletal Muscle Using Intravascular Tracer Data: Importance for Modeling Transcapillary Exchange

Claudio Cobelli, Paolo Vicini, Leif C. Groop, 1998, Annals of Biomedical Engineering.

A Multi-Region Distributed Model of Glucose Kinetics in the Human Myocardium

C. Cobelli, M. Saccomani, P. Vicini, 1994 .

The status of pharmacometrics in pregnancy: highlights from the 3rd American conference on pharmacometrics

P. Vicini, D. Mattison, M. Hebert, 2012, British journal of clinical pharmacology.

A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist

E. Sijbrands, P. Vicini, S. Hoefman, 2021, CPT: pharmacometrics & systems pharmacology.

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

B. Wang, A. Popel, P. Vicini, 2019, Royal Society Open Science.

Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase AUTHORS:

S. Yamazaki, H. Zou, P. Vicini, 2014 .

Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase AUTHORS:

S. Yamazaki, H. Zou, P. Vicini, 2014 .

AENDO June 39/6

C. Cobelli, K. Yarasheski, A. Avogaro, 1999 .

Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus.

P Vicini, U Ruotsalainen, C Cobelli, 1997, The Journal of clinical investigation.

Triglyceride enrichment of HDL does not alter HDL-selective cholesteryl ester clearance in rabbits.

P. Vicini, G. Lewis, K. Adeli, 2001, Journal of lipid research.

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

P. Vicini, M. Taboada, Nancy Lee, 2019, Clinical and translational science.

A modeling approach to quantify the direct ketogenic effect of ethanol in humans

G. Toffolo, A. Tiengo, P. Vicini, 1998 .

Metabolism‐based cyclophosphamide dosing for hematopoietic cell transplant

Brian R. Phillips, P. Vicini, G. McDonald, 2005, Clinical pharmacology and therapeutics.

clamp technique deconvolution: validation with the tracer-to-tracee Glucose production during an IVGTT by

D. Allison, C. Cobelli, D. Schoeller, 2011 .

alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes.

C. Cobelli, K. Usadel, P. Vicini, 1999, Diabetes care.

Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics.

M. MacCoss, D. Salinger, P. Vicini, 2010, Analytical chemistry.

RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801.

T. R. Johnson, P. Vicini, Dalia Kalabat, 2014, Investigative ophthalmology & visual science.

Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

P. Vicini, M. Karlsson, B. Agoram, 2018, Clinical pharmacology and therapeutics.

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite Carboxyethylphosphoramide mustard

P. Vicini, G. McDonald, J. Slattery, 2004, Clinical pharmacology and therapeutics.

Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic

Ravi Iyengar, Darrell R. Abernethy, Paolo Vicini, 2011 .

Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo-α-Acetylmethadol

P. Vicini, E. Kharasch, D. Whittington, 2005 .

Approaches to population kinetic analysis with application to metabolic studies.

A. Schumitzky, C. Cobelli, P. Vicini, 1998, Advances in experimental medicine and biology.

Personalized Dosing of Cyclophosphamide in the Total Body Irradiation–Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy

D. Salinger, F. Appelbaum, P. Vicini, 2009, Clinical pharmacology and therapeutics.

Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success

G. Genin, T. Yankeelov, G. An, 2016, Annals of Biomedical Engineering.

Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach

Brian R. Phillips, D. Salinger, P. Vicini, 2006, Clinical Cancer Research.

Effects of Cranberry Juice on Pharmacokinetics of β-Lactam Antibiotics following Oral Administration

Brian R. Phillips, D. Salinger, P. Vicini, 2009, Antimicrobial Agents and Chemotherapy.

Effects of Cranberry Juice on Pharmacokinetics of (cid:2) -Lactam Antibiotics following Oral Administration (cid:1)

Brian R. Phillips, D. Salinger, P. Vicini, 2009 .

1 Effects of Cranberry Juice on the Pharmacokinetics of Beta-lactam Antibiotics Following Oral Administration

Brian R. Phillips, D. Salinger, P. Vicini, 2009 .

Biological monitoring of controlled toluene exposure

P. Vicini, D. Kalman, M. Morgan, 1998, International archives of occupational and environmental health.

Pharmacokinetic-Pharmacodynamic and Response Sensitization Modeling of the Intraocular Pressure-Lowering Effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270)

P. Vicini, C. Xiang, K. Luu, 2009, Journal of Pharmacology and Experimental Therapeutics.

A review of quantitative modeling of B cell responses to antigenic challenge

P. Vicini, S. Nayak, T. Hickling, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Amoxicillin Pharmacokinetics in Pregnant Women: Modeling and Simulations of Dosage Strategies

P. Vicini, M. Hebert, D. Shen, 2007, Clinical pharmacology and therapeutics.

Robust Population Pharmacokinetic Experiment Design

Andrew C. Hooker, Paolo Vicini, Michael G. Dodds, 2005, Journal of Pharmacokinetics and Pharmacodynamics.

POPED, a software for optimal experiment design in population kinetics

M. Foracchia, Andrew C. Hooker, Paolo Vicini, 2004, Comput. Methods Programs Biomed..

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

Paolo Vicini, Liusong Yin, P. Vicini, 2015, Cellular immunology.

Double isotope tracer method for measuring fractional zinc absorption: theoretical analysis.

C. Cobelli, J. King, P. Vicini, 2002, American journal of physiology. Endocrinology and metabolism.

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.

P. Vicini, H. Agersø, 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software.

P Vicini, H Golde, P. Vicini, 1998, Journal of pharmaceutical sciences.

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.

Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

Paolo Vicini, Shinji Yamazaki, Bill J Smith, 2012, Journal of Pharmacology and Experimental Therapeutics.

JPET #188870 1 TITLE: Pharmacokinetic-Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Anti-tumor Efficacy in Human Tumor Xenograft Mouse Models AUTHORS:

J. Christensen, S. Yamazaki, Qiuhua Li, 2011 .

SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies.

C Cobelli, D M Foster, H Golde, 1998, Metabolism: clinical and experimental.

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

Greg M. Thurber, A. Iagaru, D. Wolf, 2018, Clinical pharmacology and therapeutics.

Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside

Paolo Vicini, Shinji Yamazaki, Mary E Spilker, 2016, Expert opinion on drug metabolism & toxicology.

Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1

Paolo Vicini, Hui Wang, Shinji Yamazaki, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Translational Pharmacokinetic-Pharmacodynamic Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros

S. Yamazaki, H. Zou, P. Vicini, 2014 .

Opportunities for quantitative translational modelling in Oncology.

Juan A. Delgado-SanMartin, P. Vicini, R. Jena, 2020, Clinical pharmacology and therapeutics.

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total

P. Vicini, J. Hood, I. González-García, 2021, Pharmaceutics.

Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers

P Vicini, AC Heatherington, Steven W. Martin, 2015, CPT: pharmacometrics & systems pharmacology.

A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics

P. Vicini, T. Hickling, Xiaoying Chen, 2013, The AAPS Journal.

Development of a Population Pharmacokinetics‐Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration

P. Vicini, D. Blough, J. McCune, 2010, Journal of clinical pharmacology.

A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients

B. Sandmaier, D. Salinger, P. Vicini, 2009, Clinical Cancer Research.

Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development

Paolo Vicini, Mary E Spilker, Pratap Singh, 2016, Cytometry. Part B, Clinical cytometry.

Catch-bond model derived from allostery explains force-activated bacterial adhesion.

Lina M. Nilsson, P. Vicini, V. Vogel, 2006, Biophysical journal.

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade

Bing Wang, Paolo Vicini, Aleksander S Popel, 2019, Scientific Reports.

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

A. Gupta, P. Vicini, P. Dennis, 2018, Clinical pharmacology and therapeutics.

Multiscale Modeling in Drug Discovery and Development: Future Opportunities and Present Challenges

P Vicini, P. Vicini, 2010, Clinical pharmacology and therapeutics.

Pubertal Adolescent Male-Female Differences in Insulin Sensitivity and Glucose Effectiveness Determined by the One Compartment Minimal Model

C. Cobelli, P. Vicini, W. Sivitz, 2000, Pediatric Research.

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models

Bernhard O. Palsson, Paolo Vicini, Mary E. Spilker, 2013, BMC Systems Biology.

Mathematical modeling and synthetic

Paolo Vicini, Andrew McCulloch, Jan Tornell, 2009 .

Predicting Human Tumor Drug Concentrations from a Preclinical Pharmacokinetic Model of Temozolomide Brain Disposition

Paolo Vicini, P. Vicini, G. Kruh, 2007, Clinical Cancer Research.

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer

B. Wang, A. Popel, E. Gabrielson, 2019, The AAPS Journal.

A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration‐Time Curve in Hematopoietic Cell Transplantation Recipients

B. Sandmaier, D. Salinger, P. Vicini, 2012, Journal of clinical pharmacology.

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly

David Baker, M. Welland, P. Vicini, 2017, Nature Communications.

Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies

Paolo Vicini, Wei-Zhu Zhong, Kenneth T. Luu, 2013, The AAPS Journal.

Disposition of Artesunate and Dihydroartemisinin after Administration of Artesunate Suppositories in Children from Papua New Guinea with Uncomplicated Malaria

Paolo Vicini, M. Alpers, P. Vicini, 2004, Antimicrobial Agents and Chemotherapy.

Forearm Nitric Oxide Balance, Vascular Relaxation, and Glucose Metabolism in NIDDM Patients

C. Cobelli, A. Avogaro, A. Tiengo, 1997, Diabetes.

A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans

Paolo Vicini, Kok-yong Seng, Ivan A. Nestorov, 2006, 2006 International Conference of the IEEE Engineering in Medicine and Biology Society.

Assessing Convergence of Markov Chain Monte Carlo Simulations in Hierarchical Bayesian Models for Population Pharmacokinetics

Paolo Vicini, Michael G. Dodds, P. Vicini, 2004, Annals of Biomedical Engineering.

from a two-compartment model Undermodeling affects minimal model indexes: insights

C. Cobelli, R. Rizza, K. Polonsky, 2011 .

Physiologically Based Pharmacokinetic Modeling of Drug Disposition in Rat and Human: A Fuzzy Arithmetic Approach

Paolo Vicini, Kok-Yong Seng, Ivan Nestorov, 2008, Pharmaceutical Research.

Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors

Bing Wang, Paolo Vicini, Aleksander S. Popel, 2019, Front. Oncol..

Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability

R. Brasch, H. Daldrup-Link, P. Vicini, 2005, Journal of magnetic resonance imaging : JMRI.

Integrated model of hepatic and peripheral glucose regulation for estimation of endogenous glucose production during the hot IVGTT.

Paolo Vicini, P. Vicini, Kevin M Krudys, 2005, American journal of physiology. Endocrinology and metabolism.

Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors

P. Vicini, J. Gallo, S. Pulfer, 2004, Clinical Cancer Research.

Preserved relative dispersion but blunted stimulation of mean flow, absolute dispersion, and blood volume by insulin in skeletal muscle of patients with essential hypertension.

C. Cobelli, V. Oikonen, U. Ruotsalainen, 1998, Circulation.

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Alex Phipps, Paolo Vicini, James W. T. Yates, 2019, CPT: pharmacometrics & systems pharmacology.

Severity of HCV-Induced Liver Damage Alters Glucose Homeostasis in Noncirrhotic Patients with Chronic HCV Infection

C. Cobelli, K. Usadel, G. Toffolo, 2000, Digestion.

Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments

Paolo Vicini, Andrew Hooker, P. Vicini, 2005, The AAPS Journal.

The hot IVGTT two-compartment minimal model: indexes of glucose effectiveness and insulin sensitivity.

Claudio Cobelli, Paolo Vicini, Andrea Caumo, 1997, American journal of physiology. Endocrinology and metabolism.

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly

David Baker, M. Welland, P. Vicini, 2017, Nature Communications.

Objective quantification of acetylcholine receptor aggregation using fast Fourier transforms

Paolo Vicini, Kok-Yong Seng, Xavier Figueroa-Masot, 2007, Comput. Methods Programs Biomed..

Physiologically based pharmacokinetic model of midazolam disposition during pregnancy

Paolo Vicini, Marilee A. Andrew, P. Vicini, 2008, 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Whither Pharmacometrics?: Present State and Future Choices

P Vicini, P. Vicini, B P Smith, 2014, Clinical pharmacology and therapeutics.

Evaluation of Pet Modeling Approaches of [ 18 Fdg]Fluorodeoxyglucose Kinetics on Heart and Brain Data

C. Cobelli, A. Bertoldo, P. Vicini, 1997 .

Estimating in Vitro Mitochondrial Oxygen Consumption During Muscle Contraction and Recovery: A Novel Approach that Accounts for Diffusion

Paolo Vicini, Ranjan K. Dash, Bradley M. Bell, 2005, Annals of Biomedical Engineering.

Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data

C. Cobelli, P. Vicini, P. Nuutila, 1997, Annals of Biomedical Engineering.

Is the minimal model too minimal?

C. Cobelli, A. Caumo, P. Vicini, 1996, Diabetologia.

Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies

P. Vicini, E. Kraynov, B. Kuang, 2013, The AAPS Journal.

Noncompartmental and compartmental approaches to pharmacokinetic data analysis

P. Vicini, D. Foster, 2022, Atkinson's Principles of Clinical Pharmacology.

Non-Compartmental and Compartmental Approaches to Pharmacokinetic Data Analysis

Paolo Vicini, David M. Foster, P. Vicini, 2013 .

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Alex Phipps, Lourdes Cucurull-Sanchez, Jon Timmis, 2019, CPT: pharmacometrics & systems pharmacology.

A Model‐Based Meta‐Analysis of the Effect of Latanoprost Chronotherapy on the Circadian Intraocular Pressure of Patients With Glaucoma or Ocular Hypertension

P. Vicini, D. Nickens, S. Raber, 2010, Clinical pharmacology and therapeutics.

Kinetic Modeling of Contrast-Enhanced MRI: An Automated Technique for Assessing Inflammation in the Rheumatoid Arthritis Wrist

Paolo Vicini, Mary E. Spilker, Jill C. Gardner, 2007, Annals of Biomedical Engineering.

Impact of cyclosporine and low‐dose steroid therapy on insulin sensitivity and beta‐cell function in patients with longterm liver grafts

C. Cobelli, K. Usadel, B. Markus, 2001 .

Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy.

C. Cobelli, K. Usadel, G. Toffolo, 2000, Transplantation.

Impact of cyclosporine and low-dose steroid therapy on insulin sensitivity and beta-cell function in patients with long-term liver grafts

C. Cobelli, K. Usadel, B. Markus, 2001, Transplant international : official journal of the European Society for Organ Transplantation.

A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non‐bleeding subjects

P. Vicini, S. Nayak, A. Heatherington, 2016, Journal of thrombosis and haemostasis : JTH.

An Evaluation of Population D-Optimal Designs Via Pharmacokinetic Simulations

Andrew C. Hooker, Paolo Vicini, Marco Foracchia, 2004, Annals of Biomedical Engineering.

Multiscale Modeling in the Clinic: Drug Design and Development

G. An, A. Popel, Xiaobo Zhou, 2016, Annals of Biomedical Engineering.

Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology

P. Vicini, T. Hickling, N. Standifer, 2019, CPT: pharmacometrics & systems pharmacology.

The System for Population Kinetics: Open Source Software for Population Analysis

Paolo Vicini, P. Vicini, 2009, Int. J. Open Source Softw. Process..

The system for population kinetics

Paolo Vicini, P. Vicini, 2008 .

Pharmacokinetics and Pharmacodynamics

P. Vicini, 2006 .

Insulin sensitivity and beta-cell secretion after liver transplantation in patients with acute liver failure.

C. Cobelli, K. Usadel, G. Toffolo, 2001, Transplantation proceedings.

Identifiability and interval identifiability of mammillary and catenary compartmental models with some known rate constants.

P Vicini, J J DiStefano, J. DiStefano, 2000, Mathematical biosciences.

Clinical Pharmacology: a Discipline at the Nexus Between Translational Science and Precision Medicine: Commentary on “Enhancing Value of Clinical Pharmacodynamics in Oncology Drug Development: An Alliance Between Quantitative Pharmacology and Translational Science”

P. Vicini, L. Roskos, 2017, Clinical pharmacology and therapeutics.

A Priori Identifiability of Distributed Models of Blood–Tissue Exchange

Claudio Cobelli, Paolo Vicini, C. Cobelli, 1999, Annals of Biomedical Engineering.

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Paolo Vicini, Deepak Dalvie, Chad Ray, 2016 .

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation

Paolo Vicini, Danny D Shen, David L Veenstra, 2009, Pharmacogenetics and genomics.

Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease.

C. Cobelli, K. Usadel, G. Toffolo, 1999, Experimental and clinical endocrinology & diabetes.

Evidence for impaired glucose effectiveness in cirrhotic patients after liver transplantation.

C. Cobelli, K. Usadel, G. Toffolo, 2000, Metabolism: clinical and experimental.

Undermodeling affects minimal model indexes

C. Cobelli, K. Yarasheski, A. Avogaro, 1999 .

Multiscale Modeling in the Clinic: Drug Design and Development

Colleen E. Clancy, Paolo Vicini, Aleksander S. Popel, 2016, Annals of Biomedical Engineering.

Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

P. Vicini, M. Stroh, Dan G. Duda, 2014, CPT: pharmacometrics & systems pharmacology.

Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors

S. Yamazaki, P. Vicini, Ying Jiang, 2013, Drug Metabolism and Disposition.

Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group

D. Salinger, P. Vicini, D. Blough, 2009, Journal of clinical pharmacology.

An Evaluation of Extended vs. Weighted Least Squares for Parameter Estimation in Physiological Modeling

Paolo Vicini, Mary E. Spilker, P. Vicini, 2001, J. Biomed. Informatics.

Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique.

Claudio Cobelli, Paolo Vicini, Andrea Caumo, 1999, American journal of physiology. Endocrinology and metabolism.

Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique.

P Vicini, C Cobelli, A Caumo, 1999, The American journal of physiology.

Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical Practice

C. Cobelli, P. Vicini, S. Caritis, 2009, Clinical pharmacology and therapeutics.

Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success

Thomas E. Yankeelov, Paolo Vicini, Aleksander S. Popel, 2016, Annals of Biomedical Engineering.

Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys

P. Vicini, Michael G. Dodds, J. Visich, 2005, The AAPS Journal.

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

Greg M. Thurber, A. Iagaru, D. Wolf, 2018, Clinical pharmacology and therapeutics.

Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models

P. Vicini, G. Lythe, J. Yates, 2021, CPT: pharmacometrics & systems pharmacology.

The hot IVGTT minimal models: simultaneous assessment of glucose disposal indices and hepatic glucose release

Paolo Vicini, C. Cobelli, A. Caumo, 1997 .

27th Annual Inter national Conference of the IEEE Engineering in Medicine and Biology Society

T. Tamura, J. Príncipe, H. Galiana, 2005 .

Relationship between Glucose Metabolism and Height and Weight Velocity in Early Puberty 440

C. Cobelli, P. Vicini, W. Sivitz, 1998, Pediatric Research.

Removal of catheter distortion in multiple indicator dilution studies: a deconvolution-based method and case studies on glucose blood-tissue exchange

C. Cobelli, G. Sparacino, P. Marraccini, 1997, Medical and Biological Engineering and Computing.

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors.

N. Rizvi, P. Vicini, J. Infante, 2018, Annals of Oncology.

Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase

S. Yamazaki, H. Zou, P. Vicini, 2015, Drug Metabolism and Disposition.

Glucose effectiveness and insulin sensitivity from the minimal models: consequences of undermodeling assessed by Monte Carlo simulation

C. Cobelli, A. Caumo, P. Vicini, 1999, IEEE Transactions on Biomedical Engineering.